Hepatitis B reactivation with fulminant hepatitis during rituximab chemotherapy in a patient with follicular lymphoma

Basit Öğe Kaydı
dc.contributor.authorAcar, Kadir
dc.contributor.authorGöktepe, Mevlüt Hakan
dc.contributor.authorPolat, İlker
dc.contributor.authorAtalay, Hüseyin
dc.date.accessioned2020-03-26T18:06:07Z
dc.date.available2020-03-26T18:06:07Z
dc.date.issued2010
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractA 52-year-old man was diagnosed Follicular lymphoma with autoimmune hemolytic anemia. At time of diagnosis his HBs Ag was (+), Anti-HBs (-), and HBV DNA was negative. Chemotherapy was interrupted after tree cycles of R-CVP due to elevated liver enzyme. At that time HBV DNA became positive. Lamivudine therapy was started, whereas patient died due to fulminant hepatic failure. The high morbidity and mortality of this complication is one of the major obstacles to completing the standard treatment for lymphoma in HBV carriers. Thus, preventive therapy with nucleoside or nucleotide analogs should be started before the chemotherapy to prevent HBV reactivation.en_US
dc.identifier.endpage93en_US
dc.identifier.issn1304-3889en_US
dc.identifier.issue1en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage92en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12395/25626
dc.identifier.volume7en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.relation.ispartofEuropean Journal of General Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectHepatitis B reactivationen_US
dc.subjectLamuvudineen_US
dc.subjectLymphomaen_US
dc.subjectRituximaben_US
dc.titleHepatitis B reactivation with fulminant hepatitis during rituximab chemotherapy in a patient with follicular lymphomaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu